Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
MILONTIN (phensuximide) is an oral succinimide anticonvulsant approved in 1953 for the treatment of absence seizures (petit mal epilepsy). The drug works by suppressing the spike-and-wave discharge pattern characteristic of absence seizures, though its exact mechanism of action remains incompletely understood. It is typically used as monotherapy or adjunctive therapy in patients with generalized absence seizures.
With LOE approaching and competitive pressure at 30%, this product is in defensive maintenance mode with minimal commercial expansion opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
MILONTIN offers limited career advancement opportunities due to its mature lifecycle stage and approaching loss of exclusivity. Working on this product typically involves defensive commercial strategies, cost optimization, and legacy brand management rather than growth-oriented innovation.
Worked on MILONTIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.